SCHEMBL14802464

SCHEMBL14802464

Cc1cc(-c2ccc(CNC(=O)c3ccc(Br)cn3)cn2)ccn1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 3/20 0.48
WNT3A P56704 13/20 0.48
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1912371 0.87 WNT3A (0.45) WNT3ASMN1; SMN2
SCHEMBL17243385 0.85 WNT3A (0.55) WDR5WNT3A
SCHEMBL249965 0.85 WNT3A (0.54) WDR5WNT3A
SCHEMBL10258532 0.85 PTGES (0.41) SMN1; SMN2
SCHEMBL17243386 0.83 WNT3A (0.46) WDR5WNT3A
SCHEMBL249342 0.82 WNT3A (0.66) WNT3A
SCHEMBL249160 0.81 WNT3A (0.53) WDR5WNT3A
SCHEMBL10258040 0.81 WNT3A (0.53) WDR5WNT3A
SCHEMBL247828 0.80 WNT3A (0.51) WDR5WNT3A
SCHEMBL248465 0.79 WNT3A (0.53) WDR5WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181235-B2 Substituted pyridines for modulating the WNT signaling pathway NOVARTIS AG (CH) 2015-11-10 US disclosed
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY NOVARTIS AG (CH) 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY WNT3A, WNT1, WNT3 WDR5 580/4885WNT3A 1/4885SMN1; SMN2 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.